New hope for japanese men with tough prostate cancer?
NCT ID NCT06104449
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested a new drug, opevesostat (MK-5684), in 7 Japanese men with a type of advanced prostate cancer that no longer responds to standard hormone therapy. The main goals were to check the drug's safety and how the body processes it. This is a first step to see if the drug might help control the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Cancer Center Hospital East ( Site 0001)
Kashiwa, Chiba, 277-8577, Japan
-
Toho University Sakura Medical Center ( Site 0003)
Sakura, Chiba, 285-8741, Japan
-
Yokohama City University Medical Center ( Site 0002)
Yokohama, Kanagawa, 232-0024, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Chemo combo vs. radioactive drug: which tames aggressive prostate cancer?
- Can a new pill outsmart resistant prostate cancer?
- Can a radioactive 'Smart Bomb' outsmart advanced prostate cancer?
- Can an immune booster make hormone therapy work better against prostate cancer?
- Can a pill outsmart Tumors' defenses?
- Can a smart drug deliver a toxic payload to prostate cancer cells?